{"id":180729,"date":"2026-06-11T09:26:35","date_gmt":"2026-06-11T07:26:35","guid":{"rendered":"https:\/\/www.bcfi.be\/?post_type=vraag_van_de_week&p=180729"},"modified":"2026-06-11T10:04:51","modified_gmt":"2026-06-11T08:04:51","slug":"vraag-van-de-week-24-denosumab-en-elektrolytstoornissen","status":"publish","type":"vraag_van_de_week","link":"https:\/\/h.bcfi.be\/nl\/vraag-van-de-week\/vraag-van-de-week-24-denosumab-en-elektrolytstoornissen\/","title":{"rendered":"Vraag van de week 24 : denosumab en elektrolytstoornissen"},"featured_media":0,"template":"","class_list":["post-180729","vraag_van_de_week","type-vraag_van_de_week","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/h.bcfi.be\/nl\/wp-json\/wp\/v2\/vraag_van_de_week\/180729","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/h.bcfi.be\/nl\/wp-json\/wp\/v2\/vraag_van_de_week"}],"about":[{"href":"https:\/\/h.bcfi.be\/nl\/wp-json\/wp\/v2\/types\/vraag_van_de_week"}],"wp:attachment":[{"href":"https:\/\/h.bcfi.be\/nl\/wp-json\/wp\/v2\/media?parent=180729"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}